BiotechTube
Home/Pipeline/bri-cel (BAY 2413334)

bri-cel (BAY 2413334)

Relapsed/Refractory Multiple Myeloma

Phase IActive, recruitingNCT06134528

Key Facts

Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase I
Status
Active, recruiting
Company
Bayer

About Bayer

Bayer AG's mission is 'Health for all, Hunger for none,' focusing on advancing healthcare and food security through science-led innovation. The company has achieved significant scale and diversification, most notably through the transformative acquisition of Monsanto, establishing a leading position in agricultural sciences. Its strategy centers on driving growth in its core pharmaceutical pipeline—particularly in oncology, cardiology, and cell & gene therapy—while navigating legacy legal challenges and optimizing its portfolio to enhance shareholder value and operational focus.

View full company profile

Therapeutic Areas

OncologyCardiologyOphthalmologyWomen's HealthCell & Gene Therapy

Other Relapsed/Refractory Multiple Myeloma Drugs

DrugCompanyPhase
Aplidin (plitidepsin)PharmaMarApproved (Conditional - AU)
TECVAYLI + DARZALEX FASPROjohnson-and-johnson-innovative-medicineApproved
LinvoseltamabRegeneronPhase 3
Blenrep (belantamab mafodotin)GSKPhase III
CAR T-Cell Therapy ProgramDr. Reddy's LaboratoriesDevelopment
HDP-101Heidelberg PharmaPhase I/IIa
inobrodib + Pd (InoPd)CellCentricPhase 1/2
CT053CARsgen TherapeuticsPhase Ib/II
CT059CARsgen TherapeuticsPhase I
P-BCMA-ALLO1Poseida TherapeuticsPhase 1
P-BCMA-101Poseida TherapeuticsPhase 1/2
ABBV-383AbbViePhase 1